收费全文 | 48069篇 |
免费 | 2269篇 |
国内免费 | 234篇 |
耳鼻咽喉 | 759篇 |
儿科学 | 831篇 |
妇产科学 | 797篇 |
基础医学 | 6213篇 |
口腔科学 | 1309篇 |
临床医学 | 3279篇 |
内科学 | 11791篇 |
皮肤病学 | 611篇 |
神经病学 | 3940篇 |
特种医学 | 1674篇 |
外科学 | 8307篇 |
综合类 | 191篇 |
一般理论 | 3篇 |
预防医学 | 1694篇 |
眼科学 | 700篇 |
药学 | 3874篇 |
中国医学 | 118篇 |
肿瘤学 | 4481篇 |
2023年 | 240篇 |
2022年 | 492篇 |
2021年 | 817篇 |
2020年 | 436篇 |
2019年 | 623篇 |
2018年 | 735篇 |
2017年 | 574篇 |
2016年 | 718篇 |
2015年 | 739篇 |
2014年 | 963篇 |
2013年 | 1286篇 |
2012年 | 2048篇 |
2011年 | 2219篇 |
2010年 | 1276篇 |
2009年 | 1090篇 |
2008年 | 2070篇 |
2007年 | 2273篇 |
2006年 | 2234篇 |
2005年 | 2279篇 |
2004年 | 2218篇 |
2003年 | 2252篇 |
2002年 | 2249篇 |
2001年 | 1727篇 |
2000年 | 1878篇 |
1999年 | 1609篇 |
1998年 | 616篇 |
1997年 | 491篇 |
1996年 | 452篇 |
1995年 | 390篇 |
1994年 | 379篇 |
1993年 | 340篇 |
1992年 | 1202篇 |
1991年 | 995篇 |
1990年 | 992篇 |
1989年 | 1009篇 |
1988年 | 915篇 |
1987年 | 900篇 |
1986年 | 838篇 |
1985年 | 821篇 |
1984年 | 573篇 |
1983年 | 459篇 |
1982年 | 241篇 |
1979年 | 503篇 |
1978年 | 287篇 |
1977年 | 266篇 |
1975年 | 223篇 |
1974年 | 240篇 |
1971年 | 243篇 |
1969年 | 235篇 |
1968年 | 221篇 |
Research design and methods: This multicenter, open-label, single-group, prospective interventional study evaluated changes in total gait-related scores of the Part II/III Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Freezing of Gait Questionnaire (FOG-Q) in 31 Parkinson’s disease patients treated with istradefylline. Gait analysis by portable gait rhythmogram was performed.
Results: MDS-UPDRS Part III gait-related total scores significantly decreased at Weeks 4–12 from baseline with significant improvements in gait, freezing of gait, and postural stability. Significant decreases in MDS-UPDRS Part II total scores and individual item scores at Week 12 indicated improved daily living activities. At Week 12, there were significant improvements in FOG-Q, new FOG-Q, and overall movement per 48 h measured by portable gait rhythmogram. Adverse events occurred in 7/31 patients.
Conclusions: Istradefylline improved gait disorders in Parkinson’s disease patients complicated with freezing of gait, improving their quality of life. No unexpected adverse drug reactions were identified.
Trial registration: UMIN-CTR (UMIN000020288). 相似文献
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Findings: A 30-year-old man with complete paraplegia used the HAL® for 1 month (10 sessions) using his remaining muscle activity, including hip flexor and upper limb activity. Electromyography was used to evaluate muscle activity of the gluteus maximus, tensor fascia lata, quadriceps femoris, and hamstring muscles in synchronization with the Vicon motion capture system. A HAL® session included a knee extension session with the hip flexor and voluntary gait with upper limb activity. After using the HAL® for one month, the patient’s manual muscle hip flexor scores improved from 1/5 to 2/5 for the right and from 2/5 to 3/5 for the left knee, and from 0/5 to 1/5 for the extension of both knees.
Conclusion/clinical relevance: Knee extension sessions with HAL®, and hip flexor and upper-limb-triggered HAL® ambulation seem a safe and feasible option in a patient with complete paraplegia due to spinal cord injury. 相似文献